『Osteoporosis treatment ‘Bonseron Tablet’ launched once a week』
As of July 1, KyungDong Pharm Co., Ltd. has launched a bisphosphonate-based osteoporosis treatment. ‘Bonseron Tablet (Sodium Risedronate 35mg)’releases.
Bonseron Tablet is a bisphosphonate-based osteoporosis treatment product containing 35 mg of risedronate sodium as an ingredient. It is a product that effectively treats osteoporosis when taken once a week.
Bonseron tablets improve patients' medication compliance by taking them once a week, and have the same effect as the daily 5mg formulation. In addition, it is an effective product for the treatment and prevention of osteoporotic fractures due to its rapid onset of effect compared to other bisphosphonate drugs.
According to clinical research data, it is reported to have a significant effect on vertebral and non-vertebral fractures in 6 months compared to Alendronate, which is the most prescribed treatment for osteoporosis.
In addition, Bonseron Tablet is a product that has proven its excellent effectiveness in all fracture areas including the spine, non-vertebrae, and hip joints through several clinical studies.
♤ Product Information ♤
◇ Product name: Bonseron tablets
◇ Ingredient content: Risedronate Sodium 35 mg
◇ Efficacy: Treatment and prevention of osteoporosis in women after menopause, treatment of osteoporosis in men
◇ Appearance: Light orange, oblong film-coated tablet
◇ Dosage: Adults take 35 mg tablet orally once a week.
◇ Insurance price: 5,068 won/tablet
◇ Packaging unit: 4 tablets (PTP)
◇ Product code: 648102550
※ For detailed information, including precautions for use, please refer to the product attachment and product information on the website.